SCHEMBL19976907

SCHEMBL19976907

CCOCCN/C(=N/C(=O)c1ccc(Cl)c(F)c1)Nc1n[nH]c2cc(C(F)(F)F)ccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 4/20 0.49
HDAC6 Q9UBN7 5/20 0.47
CRHR1 P34998 1/20 0.39
MAPK1 P28482 2/20 0.39
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39
SRC P12931 1/20 0.39
MAPK14 Q16539 1/20 0.39
TRPA1 O75762 2/20 0.38
MAP2K4 P45985 1/20 0.38
MAPK6 Q16659 1/20 0.38
MAPKAPK5 Q8IW41 1/20 0.38
KIT P10721 2/20 0.38
FLT3 P36888 1/20 0.38
ITK Q08881 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
MAPK8 P45983 1/20 0.37
MAPK10 P53779 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19976753 0.96 GSK3B (0.47) GSK3BHDAC6CRHR1MAPK1ABL1
SCHEMBL19976812 0.93 GSK3B (0.51) GSK3BHDAC6MAPK1TRPA1MAP2K4
SCHEMBL19976733 0.92 HDAC6 (0.47) GSK3BHDAC6CRHR1MAPK1ABL1
SCHEMBL19976763 0.90 GSK3B (0.52) GSK3BHDAC6MAPK1TRPA1MAP2K4
SCHEMBL19976828 0.89 GSK3B (0.49) GSK3BHDAC6MAPK1TRPA1MAP2K4
SCHEMBL19976815 0.87 GSK3B (0.44) GSK3BHDAC6MAPK1TRPA1MAP2K4
SCHEMBL19976729 0.86 HDAC6 (0.49) GSK3BHDAC6CRHR1MAPK1ABL1
SCHEMBL19976764 0.85 GSK3B (0.48) GSK3BHDAC6MAPK1TRPA1MAP2K4
SCHEMBL19976754 0.84 HDAC6 (0.52) GSK3BHDAC6MAPK1TRPA1MAP2K4
SCHEMBL19976829 0.84 HDAC6 (0.51) GSK3BHDAC6MAPK1TRPA1MAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9920012-B2 Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2018-03-20 US disclosed